In a legal move that further intensifies the contentious issue of gender-affirming care for minors in Texas, Attorney General Ken Paxton has taken action against an El Paso doctor, alleging the physician has run afoul of state law by providing puberty blockers and cross-sex hormones to children under 18. According to Attorney General Ken Paxton's Office, these medical practices are illegal under Senate Bill 14, which the Texas Supreme Court recently upheld.
Senate Bill 14 came into effect in September 2023, setting off waves of debates and lawsuits, some patients were as young as twelve, and growing scientific evidence is cited by supporters of the bill indicating that gender transition interventions for minors might have deleterious long-term effects, though these studies are frequently contested by medical professionals and LGBTQ+ advocacy groups. The law stipulates that any medical provider violating its terms faces serious repercussions, including the revocation of their medical license by the Texas Medical Board.
The suit filed by Paxton accuses the El Paso doctor not only of illegally administering these treatments but also of engaging in a pattern of deceptive practices, allegedly falsifying medical records, prescriptions, and billing documents to obscure the unlawfulness of the treatments provided. This suit represents a stark escalation in the enforcement of SB 14 and the latest chapter in the state's ongoing scrutiny over the provision of healthcare to transgender individuals.
"Texas is cracking down on doctors illegally prescribing dangerous 'gender transition' drugs to children," said Paxton, as per Attorney General Ken Paxton's Office, "State law forbids prescribing these interventions to minors because they have irreversible and damaging effects, any physician found doing so will be prosecuted to the full extent of the law," the consequences for those found in violation of the law appear severe, yet the debate over the ethics and legalities of such restrictions continues, the medical community itself remains divided on the approach to gender-affirming treatments for minors even as legal battles unfold.
